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VAUDRY, H., B. G. JENKS, L. VERBURG-VAN KEMENADE AND M.-C. TONON. Effect oftunicamycin o biosyn- 
thesis, processing and release of proopiomelanocortin-derived peptides in the intermediate lobe of the frog Rana 
ridibunda. PEPTIDES 7(2) 163-169, 1986.--The intermediate lobe of the pituitary gland synthesizes a glycoprotein, 
proopiomelanocortin (POMC), which is cleaved by specific proteolytic enzymes to generate several hormonal peptides. 
The purpose of the present study was to examine the possible role of the carbohydrate moiety in the synthesis, intracellular 
processing and release of POMC-derived peptides in frog (Rana ridibunda) intermediate lobe cells. In vitro incorporation of 
[3H]-labelled glucosamine gave rise to three major radioactive products. Trypsin digestion of each of these glycopeptides 
gave a single glucosamine-labelled tryptic fragment with identical chromatographic characteristics. We conclude that Rana 
POMC is glycosylated inonly one site (its y-MSH region) and that intracellular processing of this prohormone gives rise to 
smaller glycopeptides including lycosylated T-MSH. Treatment with the antibiotic tunicamycin (10 ttg/ml, 6 hr) inhibited 
the glycosylation of POMC but did not significantly alter the neosynthesis of the peptide moiety of the precursor. Pulse- 
chase experiments combined with high-performance liquid chromatography analysis of the peptides derived from POMC 
revealed that inhibition of glycosylation by tunicamycin had no effect on the enzymatic cleavage of the precursor nor on the 
release of mature peptides. Thus, it is concluded that, in the frog, glycosylation of POMC has no influence on the 
biosynthesis, processing and release of intermediate lobe hormones. 
Proopiomelanocortin Gamma-melanotropin Glycosylation Tunicamycin Processing Secretion 
MANY proteinous ecretory products of cells, or the pre- 
cursor proteins of these products, have proved to be glycosy- 
lated. The carbohydrate moiety on hormones such as human 
chorionic gonadotropin may play an important role in hor- 
monal activity at the level of the target issue [22,41]. The 
functional significance of glycosylation is less clear in the 
case where the biologically active secretory peptide is non- 
glycosylated but has a glycosylated precursor protein, as in 
the case for the peptide hormones vasopressin [10, 35, 39] 
and calcitonin [17] and their respective prohormones. 
Possibly the carbohydrate on these precursors could have an 
intracellular function such as direction of intracellular t ans- 
port or cleavage of the precursor or act as a signal during 
sorting of peptides for intracellular degradation or secretion. 
Indeed, there is evidence that glycosylation may have a 
function in packaging and transport of secretory material in 
the hypothalamo-neurohypophyseal system of the rat [11]. 
In studies concerning the functional significance of glycosy- 
lation, the precursor protein proopiomelanocortin (POMC) is 
interesting because: (1) in most species this is a glycosylated 
prohormone, (2) processing (cleavage) of this precursor is 
tissue-specific which leads to a different spectrum of pep- 
tides in different POMC-producing cell populations, and (3) 
some of the secretory products derived from this 
prohormone are glycopeptides of potential biological impor- 
tance. 
A valuable tool in the study of the functional significance 
of glycosylation has been the use of the antibiotic tunicamy- 
cin, which blocks asparagine-linked N-glycosylation of 
proteins [15,40]. Loh and Gainer [27-29] were the first to 
apply this antibiotic to studies concerning POMC-producing 
cells. They reported that in the pars intermedia of the pitui- 
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tary gland of the amphibian, Xenopus laevis, non- 
glycosylated POMC undergoes random proteolysis from 
which they concluded that the carbohydrate group of the 
prohormone may be involved in determining the direction of 
the processing. In a subsequent s udy [30] they suggested 
that the rapid proteolysis of the non-glycosylated 
prohormone might in fact reflect misrouting of proteolytic 
enzymes in the tunicamycin-treated tissue. In similar studies 
with a mouse corticotropin-producing tumor cell line [4] and 
with the pars intermedia of the mouse [19,21] it has been 
concluded that processing of POMC is not grossly altered 
when its glycosylation is prevented. 
In the amphibian pars intermedia melanotropic peptides 
are among the terminal products of the processing of POMC. 
These peptides are released in animals placed on a black 
background and thus the pars intermedia has an important 
function in regulating skin color [12,13]. We have previously 
conducted biosynthetic studies with the pars intermedia of 
the frog, Rana ridibunda [20, 44, 45]. These studies revealed 
that POMC of the frog intermediate lobe is a glycoprotein 
and that glycopeptides are among the secretory products of 
this tissue. The present study further characterizes these 
glycosylated products and examines the effects of tunicami- 
cyn treatment on biosynthesis and release of peptides from 
the frog pars intermedia. 
METHOD 
Animals 
Adult male frogs (Rana ridibunda) of about 40 g body 
weight were obtained from a commercial source (Courtard, 
St. Hilaire-de-Riez, France). Since dark-background a ap- 
tation enhances the biosynthetic activity of the intermediate 
lobe cells, the animals were placed in black tanks under 
constant illumination for 4 days. 
SDS-Electrophoretic Analysis of Newly Synthesized 
POMC/18K-Fragment 
Preliminary experiments were conducted to determine 
the treatment time with tunicamycin which gave optimum 
inhibition of glycosylation of POMC. Neurointermediate 
lobes were incubated for up to 8 hr in medium containing 10 
~g/ml tunicamycin (Sigma) at 22°C. Composition of the in- 
cubation medium was: NaCI, 112 mM; CaCI2, 2 mM; KC1, 2 
mM; Hepes (ultrograde, Calbiochem), 15 mM; glucose, 2 
mg/ml; bovine serum albumin (BSA, fraction V, Sigma), 0.3 
mg/ml. Before use the medium was gassed for 15 min with 
O2-CO2 (95-5) and the pH adjusted to 7.35. Following the 
preincubation i  tunicamycin the lobes were pulse incubated 
for 4 hr in 40/xl medium containing 40 tzCi [3H]lysine (76 
Ci/mmole, Amersham) and 40 ~Ci [3H]proline (31 Ci/mmole, 
Amersham). Tunicamycin was also present during the pulse 
incubation. Control lobes were given identical incubation 
paradigms except unicamycin was omitted from the incu- 
bation medium. Following the pulse incubation the lobes 
were homogenized in 500/~10.1 N HCI and the extracts ubmit- 
ted to SDS-gel electrophoresis a  described earlier [45]. The 
effectiveness oftunicamycin treatment in inhibiting glycosy- 
lation could be monitored on autoradiograms of the SDS-gels 
by observing the relative amount of newly synthesized 
POMC-related peptides in the higher molecular weight 
glycosylated-form and the lower molecular weight non- 
glycosylated-form. The results of the preliminary experi- 
ments indicated that a 6-hr preincubation i tunicamycin 
gave maximum inhibition of glycosylation and this preincu- 
bation time was therefore selected in an experiment to quan- 
tify the effects of the antibiotic. In this experiment the incu- 
bation conditions were exactly the same as those described 
above and 5 individual neurointermediate lobes were treated 
with tunicamycin and 5 individual obes functioned as con- 
trols. Quantification ofthe relative levels ofglycosylated and 
non-glycosylated proteins on the electrophoretogram was 
conducted by scanning densitometry (Biorad scanning den- 
sitometer model 1650) of flurograms prepared according to 
the method of Bonner and Laskey [3]. 
HPLC Analysis of Incorporation of [3H]Glucosamine 
Six neurointermediate lobes were preincubated for 6 hr in 
1 ml medium in the absence (control, n=3) or in the presence 
(n=3) of tunicamycin (10 /zg/ml). Each group was then 
incubated for 8 hr in 40 /zl medium containing I00 t~Ci 
[3H]glucosamine (40 Ci/mmol, Amersham). Previous 
pulse-chase xperiments [45] have shown that 8 hr is 
sufficient ime for processing of POMC to terminal products 
and, therefore, that the tissue following 8 hr of continuous 
labelling should contain both terminal products and all 
biosynthetic intermediates of POMC-processing. The 
composition of the incubation medium was identical to that 
described above except glucose was omitted. Each lobe was 
then extracted in 500 ~1 0.1 N HC1 and the extract stored 
frozen until analyzed by high performance liquid chromatog- 
raphy. 
Glucose was omitted from the incubation medium in the 
above exFeriment in the expectation that it might retard in- 
corporation of [3H]glucosamine. An additional experiment 
was conducted where glucose was present (2 mg/mi) during 
all incubation. 
Reverse phase HPLC was performed on a Spectra 
Physics (model SP 8000) liquid chromatograph equipped 
with a 4.6×240 mm Spherisorb 10 ODS column (Chrompack) 
as reported in [45]. The mobile phase consisted of a gradient 
established with 0.5 M formic acid/0.1 M pyridine (primary 
solvent) and 1-propanol (secondary solvent); the gradient 
used is presented in Fig. 1. The column was eluted at a flow 
rate of 2.0 ml/min. Fractions were collected every 0.5 min 
(1.0 ml) and 4 ml of scintillation fluid (Scintillator 299, Pack- 
ard) was added. All fractions were counted on a liquid scin- 
tillation analyser for 2 min (LKB Rackbeta). 
Tryptic Mapping of [3H]Glucosamine Labelled Peptides 
Five neurointermediate lobes were incubated in 40 /xl 
medium containing 100/xCi [~H]glucosamine. Labelled pep- 
tides were resolved by HPLC and three radioactive peaks 
corresponding to glycosylated peptides were isolated. These 
samples were dried, redisolved in 200/zl 15 mM Hepes buffer 
(pH 8) and incubated at 37°C with 20 p.g trypsin (DPCC 
treated, Sigma). Digestion of compounds designated I and V 
(see the Results section) was conducted for 21/2 hr in the 
presence of 20 tzg BSA whereas digestion of peak XI was 
conducted for 24 hr in the absence of BSA. Longer digestion 
time was used with peak XI as it represents large proteins 
which require more rigorous digestion conditions. Digestion 
was terminated by adding 500/zl 0.1 N HC1 and the radioac- 
tive peptide fragments were analysed by HPLC using the 
same mobile phase as described above. The gradient used for 
elution of the tryptic fragments i presented in Fig. 2. This 
gradient is less steep that the previous gradient to allow bet- 
ter resolution of small peptide fragments expected from the 
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FIG. 1. (a): SDS-gel electrophoretic analysis of the effect of tunicamycin on protein biosynthesis in neurointermediate lobes of the frog. 
Lobes were preincubated for 6 hr in the absence (control, - )  or presence of tunicamycin (+) and then incubated 4 hr in medium containing 
[aH]iysine and [aH]proline. Molecular weights of the radioactive proteins are calculated relative to the radioactive markers on the SDS-gel. 
(K=kiiodalton). (b): HPLC analysis of [3H]glucosamine labelled peptides synthesized by frog neurointermediate lobes in the absence ((3) or 
presence (C)) of tunicamycin. Lobes were preincubated for 6 hr and then incubated for 8 hr in medium containing [aH]glucosamine. HPLC 
elution gradient is given (% secondary solvent, B). Identification ofproducts has been reported [45]. Peak I corresponds toy-MSH; peak V 
to 7-MSH intermediate; peak XI contains both POMC and 18K-fragment. 
trypsin digestion. It has been applied previously in charac- 
terization of POMC-related peptides [18, 19, 33, 34, 44, 45]. 
Pulse-Chase Analysis of Processing and Release of 
POMC-Related Peptides 
Ten neurointermediate lobes were preincubated for 6 hr 
at 22°C in 1 ml medium in the absence (control; n=5) or in 
the presence (n=5) of tunicamycin. Then, the lobes were 
pulse-incubated for 4 hr in 40 /xl medium containing 
[3H]tyrosine (46 Ci/mmole), [3H]phenylalanine (120 Ci/ 
mmole), [ZH]lysine (90 Ci/mmole) and [ZH]proline (115 Ci/ 
mmole) (Amersham, 40 p, Ci each) in the absence or in the 
presence of tunicamycin, respectively. At the end of the 
pulse incubation, the lobes were rinsed with medium con- 
taining 2 mM of the homologous non-labelled amino acids 
(chase-medium) and they were then incubated separately in
500/~1 of chase-medium for 10 hr. Tunicamycin was present 
during the pulse-incubation f  the tunicamycin-treated lobes 
but was omitted from all chase incubations. At the end of the 
incubations the chase-media were collected and acidified 
with 50/zl 1 N HCI. Each lobe was extracted in 500/xl 0.1 N 
HCI. Both tissue extracts and media were submitted to 
HPLC. 
In separate xperiment [3H]lysine labelled peptides yn- 
thesized by control and tunicamycin-treated issue were iso- 
lated by HPLC and samples of one of the isolated peptides 
(peak I, see the Results section) was resubmitted to HPLC 
using shallower elution gradients than used in the experiment 
outlined above. For preparation of these peptides, pretreat- 
ment with tunicamycin was for 6 hr and the lobes were then 
incubated for 6 hr in 40 /~l medium containing 100 p, Ci 
[3H]lysine. In the case of the tunicamycin group, antibiotic 
treatment was continued uring this latter incubation. 
RESULTS 
Effects of Tunicamycin on Biosynthesis of POMC/18K- 
Fragment 
The frog neurointermediate lobe synthesizes a 36K and an 
18K protein (Fig. la, left lane). A previous study [45] has 
shown that the 36K protein is immunoprecipitable with 
antisera to both y-MSH and fl-endorphin and that it is rapidly 
synthesized during pulse-incubations and dissappears during 
chase-incubations. Therefore it was designated the 
prohormone, POMC. The 18K protein is immunoprecipita- 
hie with antiserum to y-MSH and it was thus concluded that 
it likely represents the NH2-terminal fragment of POMC. It 
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FIG. 2. HPLC analysis of radioactive tryptic fragments generated 
from trypsin digestion of [3H]glucosamine-labelled pro ucts of the 
frog pars intermedia. Neurointermediate lobes were incubated in 
[3H]glucosamine, the glucosamine-labelled p ptides were isolated 
by HPLC (see Fig. lb) and samples of these peptides were then 
submitted to trypsin digestion and the digestate analyzed by HPLC 
using the gradient shown (% secondary solvent, B). 
was designated the 18K-fragment in analogy with the 16K- 
fragment of mammalian POMC-peptide terminology. In 
tunicamycin-treated lobes there was a dramatic reduction in 
the amount of both the 36K POMC and 18K-fragment syn- 
thesized (Fig. la, right lane). In this latter tissue two new 
radioactive products are found, with molecular weights of 
33.3K and 15.5K. Presumably they represent non- 
glycosylated forms of POMC and 18K-fragment respectively. 
The preliminary experiments indicated that inhibition of 
glycosylation, exemplified by the lack of 36K POMC and 
18K-fragment, had reached a maximum with a 6 hr preincu- 
bation in tunicamycin and consequently this duration of 
treatment was used in all subsequent experiments. Den- 
sitometry of fluorograms howed that 6 hr pre-treatment 
gave 82.1---6.5% (n=5) inhibition of glycosylation of 
POMC/18K-fragment with very little effect on the level of 
radioactive amino acid incorporation into these proteins 
(tunicamycin group 105.2---14.0% (n=5) of control group). 
Characterization fGlycosyiated Peptides 
Previous studies [45] have shown that HPLC analysis re- 
solves a number of newly synthesized peptides in the 
neurointermediate lobe ofRana; these were numbered I-XI 
according to their elution position from the column. Analysis 
of lobe extracts following tissue incubation in the presence of 
[aH]glucosamine shows the presence of sugar in peaks I, V 
and XI (Fig. lb). Peak XI represents co-eluting proteins 36K 
POMC and 18K-fragment [45]. Immunoprecipitation exper- 
iments and pulse-chase analysis of biosynthesis have shown 
peak I and V to represent peptides related to y-MSH; peak V 
was designated y-MSH-intermediate and peak I designated 
y-MSH [46]. In the presence of tunicamycin there is clearly 
an inhibition of the incorporation of [3H]glucosamine into the 
glycosylated peptides and proteins (Fig. Ib). The low level of 
incorporation of radioactivity into products with elution 
times corresponding to non-glycosylated peptides of POMC 
processing (e.g., peaks II, VI and VII, see following section) 
is not understood. The HPLC prortles obtained in the exper- 
iments where glucose was omitted from the incubation 
medium (Fig. lb) were essentially the same as those obtained 
in experiments conducted with glucose in the medium (data 
not shown). Thus, the possibility that this low level of incor- 
poration reflects utilization of glucosamine in metabolic 
pathways leading to the production of amino acids, ulti- 
mately expressed inPOMC-related peptides, seems unlikely. 
The HPLC analysis of the trypsin digestate of 
[3H]glucosamine labelled y-MSH, y-MSH-intermediate and 
36K POMC/18K-fragment is shown in Fig. 2. This analysis 
indicates that, in each case, a single radioactive fragment 
was generated through trypsin digestion. The tryptic frag- 
ments generated from these various peptides had an identical 
HPLC elution time. 
Effects of Tunicamycin on Processing and Release of 
POMC-Related Peptides 
Pulse-chase analysis of the incorporation of [3H]amino 
acids shows synthesis of a number of radioactive peptides 
(Fig. 3a, upper profile). Besides the glycosylated peptides 
already mentioned, the HPLC analysis also shows produc- 
tion of des-Na-acetyl a-MSH (product II), an endorphin- 
like-peptide (product VI) and corticotropin-like intermediate 
lobe peptide, CLIP (product VII); these peptides were char- 
acterized extensively inour previous tudy [45]. The lobes of 
the tunicamycin-treated group gave rise to newly synthe- 
sized products with HPLC retention times identical to those 
of the control group with one notable exception, product V 
(Fig. 3a, lower profile). Separate analysis of product I iso- 
lated from normal and tunicamycin-treated issue revealed 
that the product synthesized by the latter tissue had a longer 
HPLC elution time when a shallower elution gradient was 
used (Fig. 3b). 
Following the chase incubation, newly-synthesized pep- 
tides were found to be present in the incubation medium 
(Fig. 3c). Each product in the medium of the tunicamycin 
treated tissue (Fig. 3c, lower profile) corresponds exactly 
with a product found in the HPLC profile of the control 
medium (Fig. 3c, upper profile), with again the exception of 
product V. Products III and IV represent NH2-terminal 
acetylated forms of des-Na-acetyl a-MSH ([20,44], see also 
the Discussion section). Product A, which we find only oc- 
cassionally to be a biosynthetic product of frog intermediate 
lobes, remains to be identified [20]. 
DISCUSSION 
The pars intermedia of the green frog, Rana ridibunda, 
synthesizes a 36K glycosylated protein which we have pre- 
viously designated as the prohormone, POMC [45]. 
Proteolytic processing of this prohormone has been shown to 
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FIG. 3. (a): HPLC analysis of newly-synthesized peptides extracted from frog neurointermediate lobes of control (upper profile) and 
tunicamycin-treated issue (lower profile). Lobes were preincubated for 6 hr, followed by a 4 hr incubation in medium containing amixture of 
radioactive amino acids and subsequently were chase-incubated for 10 hr. HPLC elution gradient is given (% secondary solvent, B). 
Identification of products has been reported previously [45]: I, y-MSH; II, des-Na-acetyi a-MSH; V, y-MSH-intermediate; VI, endorphin- 
like-peptide; VII, CLIP; VII-X, unidentified; XI, coelution of POMC/18K-fragment. (b): Analysis of elution position of radiolabelled product 
I (y-MSH) synthesized by normal and tunicamycin-treated neurointermediate lobes using a shallower HPLC elution gradient than that given in 
(a). Radiolabelling was conducted with [3H]lysine and y-MSH was isolated from lobe extracts. (c): HPLC analysis of newly synthesized 
peptides released to the chase-incubation medium of the experiment described in Fig. la. Products III and IV, whose presence isrestricted to 
the incubation medium, have been identified as the monoacetylated and diacetylated form of a-MSH respectively [20]. The identity of product 
A is unknown. 
generate several glycosylated peptides. On the basis of 
pulse-chase analysis of biosynthetic events in the pars inter- 
media of Rana, in combination with the results presented in 
the present investigation, we conclude that the biosynthetic 
sequence to produce 7-MSH involves cleavage of the 
prohormone to produce the NH2-terminal 18K-fragment of 
the POMC which is subsequently cleaved to generate first an 
intermediate peptide (designated 7-MSH-intermediate) and 
finally authentic ~/-MSH. The fact that tunicamycin was ef- 
fective in blocking the incorporation of [3H]glucosamine into 
these glycoproteins and glycopeptides indicates that their 
glycosylation is limited to the tunicamycin-sensitive 
asparagine-linked type. In that tryptic digestion of the 
glucosamine labelled products generated, in each case, only 
a single glucosamine labelled tryptic fragment, we further 
conclude that each peptide contains only a single oligosac- 
charide side-chain. As expected, each of the tryptic frag- 
ments generated from the various glycosylated products had 
identical HPLC elution times indicating that the glycosyla- 
tion site within each of the peptides is identical. Altogether 
we conclude that frog POMC possesses a single glycosyla- 
tion which is within the 7-MSH region of the prohormone. 
There appears to be considerable species differences both 
in the number of oligosaccharide side-chains attached to 
POMC and in the position of their attachment within the 
precursor molecule. POMC of another amphibian species, 
Xenopus laevis, has been shown to have a single glycosyla- 
tion which is in the 7-MSH region [33,34], identical to the 
situation we now report for the frog prohormone. Charac- 
terization of POMC-related peptides of the salmon [23] and 
dogfish pituitary gland [32] suggests that the prohormones of 
these species are not glycosylated. The lack of binding to 
concanavalin of POMC isolated from the pituitary gland of 
Prochilodus platensis has led Iturriza and Estivariz [16] to 
conclude that the prohormone of this teleost fish is also 
non-glycosylated. Similarly, biosynthetic studies indicate 
that the prohormone of the pars intermedia of the lizard, 
Anolis carolinensis, is not glycosylated [6]. Mammalian 
POMC in generally found tobe glycosylated with the carbo- 
hydrate attached in the y-MSH region of the prohormone. 
Some mammals, however, have been shown to possess ad- 
ditional glycosylations within their  POMC. Biosynthetic 
studies reveal that the pituitary of the rat and mouse synthe- 
sizes two forms of POMC, one form being glycosylated in 
the 7-MSH region only, while in the other form of the 
prohormone there is a glycosylation in the CLIP region as 
well [4, 5, 7, 14, 21-]. Finally, it has been suggested that 
porcine POMC possesses two glycosylations within its NH2- 
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terminal region, one of which may be of the O-linked type 
[2,24]. 
Processing of POMC in the pars intermedia of the frog 
yields, besides the various glycopeptides already discussed, 
a number of non-glycosylated peptides such as des-Na- 
acetyl a-MSH, CLIP and endorphin-like-peptide [45]. 
Chromatographic analysis of peptides ynthesized from the 
non-glycosylated prohormone of the tunicamycin-treated 
tissue reveals that, with the exception of the elution position 
of y-MSH-intermediate (product V), each peptide has an 
HPLC elution position which corresponds exactly to that of 
a peptide synthesized by the control tissue leading us to 
conclude that processing is occurring correctly. The fact that 
the elution position of the y-MSH-intermediate appears to 
have shifted is to be expected as this peptide is glycosylated 
in the control tissue and is non-glycosylated in the 
tunicamycin treated tissue. While a similar shift might have 
been expected for y-MSH (product I), apparently the elution 
gradient used was inadequate to show this difference; HPLC 
analysis using a shallower gradient showed that indeed 
y-MSH synthesized by tunicamycin-treated issue is a more 
hydrophobic peptide. 
We have found, during pulse-chase incubations with frog 
neurointermediate lobes, that the newly synthesized 
POMC-related peptides are slowly released [45]. This un- 
doubtly reflects a secretory process as their appearance in
the medium is susceptible to regulation by factors known to 
be involved in the control of melanotropin release in Rana.  
For example, dopamine inhibits the release of these newly 
synthesized peptides [20] and the neuropeptide thyrotropin 
releasing hormone stimulates their release [43]. The HPLC 
profile of peptides released by the tunicamycin-treated issue 
is, with again the exception of the y-MSH-intermediate, al-
most identical to that obtained from the control tissue. This, 
and the fact that there is very little difference between the 
two groups in the relative amount of radioactive peptides 
released, lead us to conclude that lack of glycosylation of 
POMC has little or no effect on the secretory process. 
In Rana, acetylation of des-Nct-acetyl a-MSH to form 
a-MSH (product III) and diacetylated a-MSH (product IV) is 
associated with the release process [20,44], and thus the 
presence of these peptides is limited to the incubation 
medium. In the mouse, where acetylation of melanotropins 
of the pars intermedia is clearly an intracellular event, 
tunicamycin was found to have a slight inhibitory effect on 
the acetylation process [19,21]. 
It is clear from our results that, within the time con- 
straints of our in vitro incubations, tunicamycin treatment 
has no apparent effect on the acetylation of Rana melano- 
tropin. 
Altogether, our results indicate that processing and re- 
lease of POMC-related peptides is apparently unaffected by 
tunicamycin treatment. If there is any incorrect cleavage of 
the non-glycosylated prohormone to give rise to incorrect or 
"atypical" peptides, then the incidence of this must be too 
low for the detection limit of our analysis. We therefore 
conclude that the carbohydrate moiety of frog POMC has no 
major role in either directing processing of the prohormone 
or in protecting the prohormone from random proteolysis. 
Similarly, our data offer no evidence that, in the tunicamycin 
treated tissue, there is misrouting of proteolytic enzymes to 
the secretory granules. 
In view of the species differences in glycosylation of 
POMC, discussed earlier, it is perhaps not surprising that 
we find no important intracellular function for the oligosac- 
charide side-chain on frog POMC. One might have expected 
a higher degree of conservation of glycosylation among spe- 
cies if the carbohydrate performed a vital intracellular func- 
tion. One generalization possible is that POMC of most spe- 
cies is glycosylated in the y-MSH region and that both 
glycosylated NH2-terminal fragments of POMC and glycosy- 
lated y-MSH are biosynthetic products of the pituitary gland 
of many species. Interestingly, while -/-MSH structures are 
reported to be very weak melanotropins [26], it has been 
suggested that the NH2-terminal fragment, or T-MSH itself, 
may have a function in regulation of the adrenal gland, not 
only in mammals [1, 8, 9, 31, 36-38] but in submammalian 
vertebrates as well [25,42]. Possibly, the carbohydrate moi- 
ety of these peptides could have an extracellular function, 
such as influencing their biological half-life or play a role in 
the interaction of these peptides with their target issue. In 
this regard it is interesting to note that glycosylated forms of 
POMC-related peptides have been reported to be less sus- 
ceptible to proteolysis by trypsin and blood proteases [29]. 
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